Skip to content
Back to Resources

Artificial intelligence–powered immune phenotyping of advanced or metastatic urothelial carcinoma clinical trial samples from hematoxylin and eosin–stained whole slide images

• First-line (1L) maintenance with avelumab, an anti–PD-L1 antibody, combined with best supportive care (BSC) significantly prolonged overall survival vs BSC alone in the JAVELIN Bladder 100 clinical trial enrolling patients with advanced or metastatic UC that had not progressed with 1L platinum-containing chemotherapy

• Results from this trial led to the approval of avelumab 1L maintenance in various countries worldwide, and the JAVELIN Bladder regimen is an established standard of care in international treatment guidelines based on level 1 evidence

• PathAI machine learning (ML) models have previously been deployed to characterize the tumor microenvironment in a range of cancer types Conway et al.
Get In Touch

Get In Touch

PathAI Media

Company Contact

Liz Storti

Chief People Officer

elizabeth.storti@pathai.com

Media Contact

Daniel Donato

LifeSci Communications

ddonato@lifescicomms.com

516-474-0554